HomeAI · summaries
Storia in 2 fonti
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Enhertu’s market conquest is continuing apace. | Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But while arriving nearly two months early, the adjuvant label comes with a catch.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
pharmaceutical-technology.com
FDA approves Enhertu for two HER2-positive early breast cancer indications
The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer.
- ·
fiercepharma.com
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Enhertu’s market conquest is continuing apace. | Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But while…